- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07951606
Safty and Efficacy of KH658 in Subjects With Diabetic Retinopathy
A Phase II Study to Evaluate the Safty and Efficacy of KH658 Gene Therapy in Participants With Diabetic Retinopathy (DR)
KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for DR could potentially reduce the treatment burden and maintain visual acuity and retinal anatomical stability
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Yan Cheng
- Telefonnummer: 86-028-81258178
- E-post: 025171@cnkh.com
Studieorter
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100730
- Peking Union Medical College Hospital
-
Kontakt:
- Youxin Chen, MD
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- West China Hospital of Sichuan University
-
Kontakt:
- Fang Lu, MD
- Telefonnummer: 028-85422114
- E-post: scudag@scu.edu.cn
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Are willing and able to sign the informed consent form (ICF);
- Male or female ≥ 18 to 85 years of age with DR secondary to diabetes mellitus Type 1 or Type 2;
- Moderately Severe NPDR or Severe NPDR (DRSS levels 47-53);
- Have a ETDRS BCVA letter score of ≥ 69 (approximately 20/40 Snellen equivalent) in the study eye at Screening;
- Have a ETDRS BCVA letter score of ≥19 (approximately 20/400 Snellen equivalent) in the fellow eye at Screening;
- No active CI-DME
Exclusion Criteria:
- Have any non-DR disease in the study eye judged by the investigator that could impact macular examination or affect central vision or visual acuity improvement (such as macular hemorrhage, central retinal vein occlusion, fovea scar, fibrosis or atrophy etc.);
- Have any vitreous hemorrhage or history of vitreous hemorrhage in the study eye;
- Presence of an implant (excluding intraocular lens), opacification of the refractive medium or miosis that affects fundus examination;
- Have a history of or presence of retinal detachment or choroidal detachment in the study eye.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: KH658 Dose 1
In-office delivers KH658 to the suprachoroidal space |
KH658 Dose 1 suprachoriodal single injection |
|
Experimentell: KH658 Dose 2
In-office delivers KH658 to the suprachoroidal space |
KH658 Dose 2 suprachoriodal single injection |
|
Aktiv komparator: Ranibizumab
Ranibizumab IVT Injection |
Administered by intravitreal injection once a month |
|
Inget ingripande: Observational Control
Observational Control |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of Participants with a ≥2 steps DRSS Improvement From Baseline in Diabetic Retinopthy
Tidsram: At Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants achieving a ≥2 steps improvement on the DRSS from baseline. |
At Week 52
|
|
Proportion of Participants Developing Vision-Threatening Events (VTEs)
Tidsram: At Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants developing VTEs. VTEs include vision-threatening complications (VTCs) and center-involved diabetic macular edema (CI-DME) requiring rescue treatment. |
At Week 52
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of Participants With Improvement, Maintanance, or Worsening in DRSS Score From Baseline
Tidsram: At Week 24, Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the proportion of participants demonstrating improvement, maintance, or worsening in the DRSS score compared to baseline. |
At Week 24, Week 52
|
|
Time to first occurrence of VTEs
Tidsram: Day 1 to Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the time to first occurrence of VTEs. |
Day 1 to Week 52
|
|
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Tidsram: Through Week 52
|
To evaluate the safty of KH658 ophthalmic injection in patients with DR, assessed by the incidence of AEs and SAEs |
Through Week 52
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of rescue treatments
Tidsram: At Week 24, Week 52
|
To evaluate the efficacy of KH658 ophthalmic injection in patients with DR, assessed by the number of rescue treatments |
At Week 24, Week 52
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Sjukdomar i det endokrina systemet
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Diabetes mellitus
- Ögonsjukdomar
- Diabetiska angiopatier
- Diabeteskomplikationer
- Näthinnesjukdomar
- Diabetisk retinopati
- Aminosyror, peptider och proteiner
- Proteiner
- Antikroppar, monoklonal, humaniserad
- Antikroppar, monoklonal
- Antikroppar
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Ranibizumab
Andra studie-ID-nummer
- KH658-40301
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .